FUSEN PHARM (01652) Has Four Products Selected as Proposed Winners in China's National Drug Procurement

Stock News

Aug 03

FUSEN PHARM (01652) announced that during the 12th round of China's national centralized drug procurement, held on July 31, 2026, four of the company's products were selected as proposed winners. These include: Nicardipine Hydrochloride Injection (2ml: 2mg, 5ml: 5mg), Azilsartan Medoxomil Potassium Tablets (40mg, 80mg), Compound Potassium Hydrogen Phosphate Injection (5ml: 1.12g of potassium dihydrogen phosphate and 1.18g of dipotassium hydrogen phosphate, calculated as K2HPO4), and Dydrogesterone Tablets (10mg).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/news/1109787639"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1109787639\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1109787639?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-03 17:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109787639","market":"us","top_or_hot":-1,"title":"FUSEN PHARM (01652) Has Four Products Selected as Proposed Winners in China's National Drug Procurement","media":"Stock News","content":"<p><b>FUSEN PHARM</b> (01652) announced that during the 12th round of China's national centralized drug procurement, held on July 31, 2026, four of the company's products were selected as proposed winners. These include: Nicardipine Hydrochloride Injection (2ml: 2mg, 5ml: 5mg), Azilsartan Medoxomil Potassium Tablets (40mg, 80mg), Compound Potassium Hydrogen Phosphate Injection (5ml: 1.12g of potassium dihydrogen phosphate and 1.18g of dipotassium hydrogen phosphate, calculated as K2HPO4), and Dydrogesterone Tablets (10mg).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FUSEN PHARM (01652) Has Four Products Selected as Proposed Winners in China's National Drug Procurement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFUSEN PHARM (01652) Has Four Products Selected as Proposed Winners in China's National Drug Procurement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-03 17:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>FUSEN PHARM</b> (01652) announced that during the 12th round of China's national centralized drug procurement, held on July 31, 2026, four of the company's products were selected as proposed winners. These include: Nicardipine Hydrochloride Injection (2ml: 2mg, 5ml: 5mg), Azilsartan Medoxomil Potassium Tablets (40mg, 80mg), Compound Potassium Hydrogen Phosphate Injection (5ml: 1.12g of potassium dihydrogen phosphate and 1.18g of dipotassium hydrogen phosphate, calculated as K2HPO4), and Dydrogesterone Tablets (10mg).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1109787639","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109787639","pubTimestamp":1785750637,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"FUSEN PHARM (01652) announced that during the 12th round of China's national centralized drug procurement, held on July 31, 2026, four of the company's products were selected as proposed winners....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","01652":"福森药业"},"translate_title":"复森医药(01652)有四个产品入选中国国家药品采购拟中标单位","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01652":1},"content_text":"FUSEN PHARM (01652) announced that during the 12th round of China's national centralized drug procurement, held on July 31, 2026, four of the company's products were selected as proposed winners. These include: Nicardipine Hydrochloride Injection (2ml: 2mg, 5ml: 5mg), Azilsartan Medoxomil Potassium Tablets (40mg, 80mg), Compound Potassium Hydrogen Phosphate Injection (5ml: 1.12g of potassium dihydrogen phosphate and 1.18g of dipotassium hydrogen phosphate, calculated as K2HPO4), and Dydrogesterone Tablets (10mg).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}